Genetic Factors in Rheumatoid Arthritis
The most critical genetic risk factor for rheumatoid arthritis is the HLA-DRB1 shared epitope (SE) alleles, particularly HLA-DRB104 and HLA-DRB101, which directly alter antigen presentation and increase autoreactive T cell populations, driving both disease susceptibility and severity. 1, 2
Primary Genetic Risk Factors
HLA Genes (Major Histocompatibility Complex)
The HLA region on chromosome 6 contains the strongest genetic associations with RA:
- HLA-DRB1 shared epitope alleles are the dominant risk factors, with polymorphisms in the amino acid sequence changing the capability to present autoantigens and increasing autoreactive T cells during thymic selection 1
- HLA-DRB104 and HLA-DRB101 are significantly associated with RA development in general populations 3
- HLA-DRB1*1402 is particularly important in Indigenous North American populations, where it drives predominantly seropositive, severe disease with familial clustering and unfavorable outcomes 2
- These HLA class II molecules present processed extracellular antigens to CD4 T cells, with their open-ended antigen-binding groove accommodating variable-length peptides 1
Non-HLA Genetic Risk Factors
Beyond HLA, multiple genes contribute to RA susceptibility and severity:
Confirmed risk genes:
- PTPN22 (rs2476601): Significantly associated with RA development, involved in immune dysregulation 3, 4
- TNF (rs1800629): Associated with RA susceptibility and disease severity 3, 5
- C5/TRAF1 region (rs10818488): Confirmed genetic risk factor for both susceptibility and severe disease course 5, 4
- TNFAIP3-OLIG3 region: Confirmed risk factor for RA development 4
Probable risk genes:
- STAT4, CTLA4, PADI4, IRF5: Listed as probable RA development risk factors 4
- PADI4 genotypes (rs11203367, rs2240340, rs11203366, rs874881): Associated with baseline disease activity scores (DAS28-CRP, HAQ-DI, CDAI) 3
Population-Specific Genetic Considerations
First-Degree Relatives (FDRs)
FDRs carry inherent genetic risk identifiable through family history:
- Serum ACPA is enriched in FDRs (~10% prevalence) and strongly associated with arthritis development 2
- Rheumatoid factor prevalence reaches ~15% in FDRs 2
- ACPA IgG variable domain glycosylation is a strong predictor of future RA development in FDRs 2
Indigenous North American Populations
These populations demonstrate unique genetic architecture:
- HLA-DRB1*1402 (almost unique to Indigenous Peoples) is the particularly important risk factor 2
- Combination of HLA-DR SE and non-SE allele DRB1*0901 associates with ACPA and earlier age of RA onset 2
- High RA prevalence with predominantly seropositive, severe disease and familial clustering 2
Genetic Factors Influencing Disease Severity
Severity-associated polymorphisms:
- TNF-alpha gene (-238G/A, -308G/A, +489G/A): Among most intensively investigated HLA-independent risk factors for severe RA 5
- IL-1beta gene (-11C/T, +3953C/T): Associated with aggressive/refractory disease 5
- IL-4 gene (-590C/T): Linked to severe disease course 5
- MMP genes (-1607 ins1G/del2G, -1612 ins/del A): Associated with disease severity 5
Biomarker associations:
- IL23R (rs7530511) and TNFRSF1A (rs748004, rs2228144): Associated with ACPA levels 3
- DHODH (rs3213422) and MTHFR (rs180113): Associated with C-reactive protein concentration 3
- IL2RA (rs2104286), IRAK3 (rs11541076), IL4R (rs1801275): Associated with rheumatoid factor levels 3
Clinical Implications
Risk Stratification Algorithm
For asymptomatic individuals:
- Assess family history (FDR status)
- Screen for HLA-DRB1 SE alleles, particularly *04 and *01
- Test for ACPA and RF
- In Indigenous populations, specifically test for HLA-DRB1*1402
For symptomatic at-risk individuals:
- High ACPA levels + RF positivity = highest risk for progression
- Dual positivity (anti-CCP + RF) strongly predicts arthritis development 2
- ACPA repertoire extent correlates with progression risk 2
Common Pitfalls
- ACPA levels fluctuate over time and can revert to seronegative state, so single measurements may be misleading 2
- The genetic risk is not solely deterministic—environmental factors, access to care, and gene-environment interactions significantly modulate disease expression 2
- Long-range linkage disequilibrium across the MHC region makes it challenging to identify independent causal variants 1
- Population-specific genetic diversity necessitates tailored genetic testing approaches rather than universal panels 1
Pharmacogenomic Considerations
Genetic markers increasingly predict treatment response: